18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
The primary objective is to compare the diagnostic performance of 18F- Fluoride PET/CT scanning to that of conventional bone scanning for detecting cancer that has spread to the bone (bone metastasis). The intent of the study is to determine whether 18F-Fluoride PET/CT will lead to improved treatment and patient outcomes.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- device : Bone Scan: F18-Fluoride PET/CT or TC-MDP
Phase: Phase 3
Ages Eligible For Study:
- Patient is ? 18 years old at the time of the drug administration (Patient may be male or female of any race / ethnicity.) - Patient or patient's legally acceptable representative cognitively provides written informed consent - Patients without known bone metastases who are newly diagnosed with ? stage 3 breast cancer, ? stage 3 lung cancer, or ? stage 2 prostate cancer (and/or PSA >10 micrograms/L), including patient with recurrent breast, lung or prostate cancer - Patient is scheduled to undergo a conventional bone scan - Patient is capable of complying with study procedures - Patient is able to remain still for duration of imaging procedure (about one hour) - Patient may have had a prior PET or PET/CT scan for staging/restaging.